Article
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
The Lancet. Oncology - 1 Oct 2016
O'Brien Susan, Jones Jeffrey A, Coutre Steven E, Mato Anthony R, Hillmen Peter, Tam Constantine, Österborg Anders, Siddiqi Tanya, Thirman Michael J, Furman Richard R, Ilhan Osman, Keating Michael J, Call Timothy G, Brown Jennifer R, Stevens-Brogan Michelle, Li Yunfeng, Clow Fong, James Danelle F, Chu Alvina D, Hallek Michael, Stilgenbauer Stephan
Abstract excerpt
BACKGROUND: The TP53 gene, encoding tumour suppressor protein p53, is located on the short arm of chromosome 17 (17p). Patients with 17p deletion (del17p) chronic lymphocytic leukaemia have poor responses and survival after chemoimmunotherapy. We assessed the activity and safety of ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase, in relapsed or refractory patients with del17p chronic lymphocytic...
Topics
Join the communities discussing this publication.